Compare CJC-1295 No DAC (Mod GRF 1-29) and Sermorelin (GHRH 1-29). Half-life stability, pituitary stimulation, and sleep/recovery benefits.
CJC-1295 (No DAC / Mod GRF 1-29) is a tetrasubstituted modified version of Sermorelin with 4 amino acid substitutions that increase its metabolic half-life from ~10 minutes to ~30 minutes, resulting in a substantially stronger and more reliable physiological GH pulse.
| Evaluation Feature | CJC-1295 (No DAC) / Mod GRF 1-29 | Sermorelin | Analytical Winner / Takeaway |
|---|---|---|---|
| In Vivo Half-Life | ~30 minutes (Tetrasubstituted) | ~10 minutes (Native GHRH 1-29) | CJC-1295 No DAC has 3x longer stability |
| Resistance to Cleavage | High (Resists DPP-IV and trypsin) | Low (Rapidly degraded in serum) | CJC-1295 produces higher GH release |
| Historical FDA History | Research grade | Historically FDA-approved (Geref) | Sermorelin has older clinical pedigree |
Both are Growth Hormone-Releasing Hormone (GHRH) receptor agonists targeting pituitary somatotropes. However, native Sermorelin is rapidly cleaved by blood dipeptidyl peptidase IV (DPP-IV), whereas CJC-1295 No DAC resists enzyme cleavage.
Sermorelin half-life is ~8-12 minutes; CJC-1295 No DAC half-life is ~30 minutes.
Both are dosed at 100mcg - 300mcg at bedtime on an empty stomach.
Both pair synergistically with Ipamorelin to create a dual pituitary pulse.
CJC-1295 (No DAC) is generally the modern preferred choice due to superior chemical stability and greater GH area-under-the-curve (AUC) release.